Anti-TREM2 antibody produced in rabbit

TREM2 (triggering receptor expressed on myeloid cells 2) is a transmembrane receptor belonging to the immunoglobulin (Ig) family. It is composed of an extracellular region containing the Ig-like domain and a cytoplasmic tail. It has a transmembrane region of 33 amino acids followed by a cytoplasmic tail. It is expressed on myeloid cells such as, macrophages found in tissue and dendritic cells, on microglial cells in the brain.

Triggering receptor expressed on myeloid cells 2 precursor recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

TREM2 (triggering receptor expressed on myeloid cells 2) is involved in bacterial phagocytosis and regulation of inflammatory response. Its presence in microglia helps to remove the neural debris i.e. amyloid β peptide (Aβ) on microglia. TREM2 suppresses the ability of microglia to phagocytize Aβ, and disturbs the pro-inflammatory activity of these cells. Parkinson′s disease (PD) is portrayed by the degeneration of dopaminergic neurons, in the substantia nigra standards compacta district of the cerebrum. TREM2 binds specifically to the ligands expressed by these dopaminergic neurons. Likewise, microgliosis is additionally involved in the progress of PD. Hence, TREM2 gene might be linked to susceptibility to PD. p.R47H polymorphism in this gene is identified with increased risk of sporadic amyotrophic sidelong sclerosis. Mutation in TREM2 is also associated with polycystic lipomembranous osteodysplaysia with sclerosing leukoencephalop.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Corresponding Antigen APREST71704.

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.